1 d Search Results


anti p vegfr1  (R&D Systems)
92
R&D Systems anti p vegfr1
Anti P Vegfr1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti p vegfr1/product/R&D Systems
Average 92 stars, based on 1 article reviews
anti p vegfr1 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
anti mouse arginase 1 arg 1 antibody  (R&D Systems)
93
R&D Systems anti mouse arginase 1 arg 1 antibody
Anti Mouse Arginase 1 Arg 1 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse arginase 1 arg 1 antibody/product/R&D Systems
Average 93 stars, based on 1 article reviews
anti mouse arginase 1 arg 1 antibody - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
human dj 1 antibody af3995  (R&D Systems)
92
R&D Systems human dj 1 antibody af3995
Human Dj 1 Antibody Af3995, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human dj 1 antibody af3995/product/R&D Systems
Average 92 stars, based on 1 article reviews
human dj 1 antibody af3995 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
human glypican 1  (R&D Systems)
92
R&D Systems human glypican 1
Human Glypican 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human glypican 1/product/R&D Systems
Average 92 stars, based on 1 article reviews
human glypican 1 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
anti ho 1  (R&D Systems)
92
R&D Systems anti ho 1
Anti Ho 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ho 1/product/R&D Systems
Average 92 stars, based on 1 article reviews
anti ho 1 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
pecam 1 alexa fluor 488 conjugated antibody  (R&D Systems)
94
R&D Systems pecam 1 alexa fluor 488 conjugated antibody
Pecam 1 Alexa Fluor 488 Conjugated Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pecam 1 alexa fluor 488 conjugated antibody/product/R&D Systems
Average 94 stars, based on 1 article reviews
pecam 1 alexa fluor 488 conjugated antibody - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
3 mbpp1 inhibitor  (Toronto Research Chemicals)
93
Toronto Research Chemicals 3 mbpp1 inhibitor
3 Mbpp1 Inhibitor, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3 mbpp1 inhibitor/product/Toronto Research Chemicals
Average 93 stars, based on 1 article reviews
3 mbpp1 inhibitor - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
2 amino 6 methyldipyrido  (Toronto Research Chemicals)
86
Toronto Research Chemicals 2 amino 6 methyldipyrido
2 Amino 6 Methyldipyrido, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/2 amino 6 methyldipyrido/product/Toronto Research Chemicals
Average 86 stars, based on 1 article reviews
2 amino 6 methyldipyrido - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
human ccl2  (R&D Systems)
93
R&D Systems human ccl2
Figure 2: Tumor expression of chemokine decoy receptors (CDR) and host genotype of CDR jointly affect breast cancer relapse. A. Effect of tumor phenotype of CDR on relapse-free survival (RFS). P for log rank = 7.5 × 10−6. The RFS curve was derived from the Kaplan-Meier estimate, and the survival differences between groups were compared by log-rank test. B. Effect of host genotype of CDR on RFS. P for log rank = 0.002 C. Joint effect of tumor phenotype and host genotype of CDR on RFS. P-values of the differences between high expression/minor genotype group and high expression/major genotype group, high expression/major genotype group and low expression/ minor genotype group, and low expression/minor genotype group and low expression/major genotype group are 0.007, 0.354, and 0.047, respectively. High expression indicates co-expression of DARC and D6, otherwise low expression. Minor genotype indicates patients with at- least-one protective minor allele, otherwise major genotype. D. Chemokine levels in the supernatant of cells detected by ELISA after 24-hour incubation. For transient transfection, 1 μg pDARC-42G or -42A, 1 μg pD6-373S or -373Y, or the combination of 1 μg variant-type DARC- 42A and 1 μg variant-type pD6-373Y were transfected. An empty expression vector was also used as a control. 72 hours after transfection, the levels of human <t>CCL2</t> and CCL5 in cell supernatants were determined with a sandwich ELISA. Columns represent the mean of three independent experiments; bars, standard error; *, P < 0.05. E. ROC curves assessing the discriminatory performance of the CDR phenotype/ genotype model and the CDR phenotype model for the prediction of disease relapse. P = 0.02 for AUC comparison.
Human Ccl2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ccl2/product/R&D Systems
Average 93 stars, based on 1 article reviews
human ccl2 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
goat fra1 antibody  (R&D Systems)
93
R&D Systems goat fra1 antibody
Figure 2: Tumor expression of chemokine decoy receptors (CDR) and host genotype of CDR jointly affect breast cancer relapse. A. Effect of tumor phenotype of CDR on relapse-free survival (RFS). P for log rank = 7.5 × 10−6. The RFS curve was derived from the Kaplan-Meier estimate, and the survival differences between groups were compared by log-rank test. B. Effect of host genotype of CDR on RFS. P for log rank = 0.002 C. Joint effect of tumor phenotype and host genotype of CDR on RFS. P-values of the differences between high expression/minor genotype group and high expression/major genotype group, high expression/major genotype group and low expression/ minor genotype group, and low expression/minor genotype group and low expression/major genotype group are 0.007, 0.354, and 0.047, respectively. High expression indicates co-expression of DARC and D6, otherwise low expression. Minor genotype indicates patients with at- least-one protective minor allele, otherwise major genotype. D. Chemokine levels in the supernatant of cells detected by ELISA after 24-hour incubation. For transient transfection, 1 μg pDARC-42G or -42A, 1 μg pD6-373S or -373Y, or the combination of 1 μg variant-type DARC- 42A and 1 μg variant-type pD6-373Y were transfected. An empty expression vector was also used as a control. 72 hours after transfection, the levels of human <t>CCL2</t> and CCL5 in cell supernatants were determined with a sandwich ELISA. Columns represent the mean of three independent experiments; bars, standard error; *, P < 0.05. E. ROC curves assessing the discriminatory performance of the CDR phenotype/ genotype model and the CDR phenotype model for the prediction of disease relapse. P = 0.02 for AUC comparison.
Goat Fra1 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat fra1 antibody/product/R&D Systems
Average 93 stars, based on 1 article reviews
goat fra1 antibody - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
anti 1  (R&D Systems)
92
R&D Systems anti 1
Figure 2: Tumor expression of chemokine decoy receptors (CDR) and host genotype of CDR jointly affect breast cancer relapse. A. Effect of tumor phenotype of CDR on relapse-free survival (RFS). P for log rank = 7.5 × 10−6. The RFS curve was derived from the Kaplan-Meier estimate, and the survival differences between groups were compared by log-rank test. B. Effect of host genotype of CDR on RFS. P for log rank = 0.002 C. Joint effect of tumor phenotype and host genotype of CDR on RFS. P-values of the differences between high expression/minor genotype group and high expression/major genotype group, high expression/major genotype group and low expression/ minor genotype group, and low expression/minor genotype group and low expression/major genotype group are 0.007, 0.354, and 0.047, respectively. High expression indicates co-expression of DARC and D6, otherwise low expression. Minor genotype indicates patients with at- least-one protective minor allele, otherwise major genotype. D. Chemokine levels in the supernatant of cells detected by ELISA after 24-hour incubation. For transient transfection, 1 μg pDARC-42G or -42A, 1 μg pD6-373S or -373Y, or the combination of 1 μg variant-type DARC- 42A and 1 μg variant-type pD6-373Y were transfected. An empty expression vector was also used as a control. 72 hours after transfection, the levels of human <t>CCL2</t> and CCL5 in cell supernatants were determined with a sandwich ELISA. Columns represent the mean of three independent experiments; bars, standard error; *, P < 0.05. E. ROC curves assessing the discriminatory performance of the CDR phenotype/ genotype model and the CDR phenotype model for the prediction of disease relapse. P = 0.02 for AUC comparison.
Anti 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti 1/product/R&D Systems
Average 92 stars, based on 1 article reviews
anti 1 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
anti hil 12rβ1 pe conjugated antibody  (R&D Systems)
94
R&D Systems anti hil 12rβ1 pe conjugated antibody
Figure 2: Tumor expression of chemokine decoy receptors (CDR) and host genotype of CDR jointly affect breast cancer relapse. A. Effect of tumor phenotype of CDR on relapse-free survival (RFS). P for log rank = 7.5 × 10−6. The RFS curve was derived from the Kaplan-Meier estimate, and the survival differences between groups were compared by log-rank test. B. Effect of host genotype of CDR on RFS. P for log rank = 0.002 C. Joint effect of tumor phenotype and host genotype of CDR on RFS. P-values of the differences between high expression/minor genotype group and high expression/major genotype group, high expression/major genotype group and low expression/ minor genotype group, and low expression/minor genotype group and low expression/major genotype group are 0.007, 0.354, and 0.047, respectively. High expression indicates co-expression of DARC and D6, otherwise low expression. Minor genotype indicates patients with at- least-one protective minor allele, otherwise major genotype. D. Chemokine levels in the supernatant of cells detected by ELISA after 24-hour incubation. For transient transfection, 1 μg pDARC-42G or -42A, 1 μg pD6-373S or -373Y, or the combination of 1 μg variant-type DARC- 42A and 1 μg variant-type pD6-373Y were transfected. An empty expression vector was also used as a control. 72 hours after transfection, the levels of human <t>CCL2</t> and CCL5 in cell supernatants were determined with a sandwich ELISA. Columns represent the mean of three independent experiments; bars, standard error; *, P < 0.05. E. ROC curves assessing the discriminatory performance of the CDR phenotype/ genotype model and the CDR phenotype model for the prediction of disease relapse. P = 0.02 for AUC comparison.
Anti Hil 12rβ1 Pe Conjugated Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti hil 12rβ1 pe conjugated antibody/product/R&D Systems
Average 94 stars, based on 1 article reviews
anti hil 12rβ1 pe conjugated antibody - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

Image Search Results


Figure 2: Tumor expression of chemokine decoy receptors (CDR) and host genotype of CDR jointly affect breast cancer relapse. A. Effect of tumor phenotype of CDR on relapse-free survival (RFS). P for log rank = 7.5 × 10−6. The RFS curve was derived from the Kaplan-Meier estimate, and the survival differences between groups were compared by log-rank test. B. Effect of host genotype of CDR on RFS. P for log rank = 0.002 C. Joint effect of tumor phenotype and host genotype of CDR on RFS. P-values of the differences between high expression/minor genotype group and high expression/major genotype group, high expression/major genotype group and low expression/ minor genotype group, and low expression/minor genotype group and low expression/major genotype group are 0.007, 0.354, and 0.047, respectively. High expression indicates co-expression of DARC and D6, otherwise low expression. Minor genotype indicates patients with at- least-one protective minor allele, otherwise major genotype. D. Chemokine levels in the supernatant of cells detected by ELISA after 24-hour incubation. For transient transfection, 1 μg pDARC-42G or -42A, 1 μg pD6-373S or -373Y, or the combination of 1 μg variant-type DARC- 42A and 1 μg variant-type pD6-373Y were transfected. An empty expression vector was also used as a control. 72 hours after transfection, the levels of human CCL2 and CCL5 in cell supernatants were determined with a sandwich ELISA. Columns represent the mean of three independent experiments; bars, standard error; *, P < 0.05. E. ROC curves assessing the discriminatory performance of the CDR phenotype/ genotype model and the CDR phenotype model for the prediction of disease relapse. P = 0.02 for AUC comparison.

Journal: Oncotarget

Article Title: Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse.

doi: 10.18632/oncotarget.4470

Figure Lengend Snippet: Figure 2: Tumor expression of chemokine decoy receptors (CDR) and host genotype of CDR jointly affect breast cancer relapse. A. Effect of tumor phenotype of CDR on relapse-free survival (RFS). P for log rank = 7.5 × 10−6. The RFS curve was derived from the Kaplan-Meier estimate, and the survival differences between groups were compared by log-rank test. B. Effect of host genotype of CDR on RFS. P for log rank = 0.002 C. Joint effect of tumor phenotype and host genotype of CDR on RFS. P-values of the differences between high expression/minor genotype group and high expression/major genotype group, high expression/major genotype group and low expression/ minor genotype group, and low expression/minor genotype group and low expression/major genotype group are 0.007, 0.354, and 0.047, respectively. High expression indicates co-expression of DARC and D6, otherwise low expression. Minor genotype indicates patients with at- least-one protective minor allele, otherwise major genotype. D. Chemokine levels in the supernatant of cells detected by ELISA after 24-hour incubation. For transient transfection, 1 μg pDARC-42G or -42A, 1 μg pD6-373S or -373Y, or the combination of 1 μg variant-type DARC- 42A and 1 μg variant-type pD6-373Y were transfected. An empty expression vector was also used as a control. 72 hours after transfection, the levels of human CCL2 and CCL5 in cell supernatants were determined with a sandwich ELISA. Columns represent the mean of three independent experiments; bars, standard error; *, P < 0.05. E. ROC curves assessing the discriminatory performance of the CDR phenotype/ genotype model and the CDR phenotype model for the prediction of disease relapse. P = 0.02 for AUC comparison.

Article Snippet: After 72 hours of transfection, the levels of human CCL2 and CCL5 in cell supernatants were determined with a sandwich ELISA (R&D systems, USA).

Techniques: Expressing, Derivative Assay, Enzyme-linked Immunosorbent Assay, Incubation, Transfection, Variant Assay, Plasmid Preparation, Control, Sandwich ELISA, Comparison